Table 4. Gleason Score in relation to localization of scan results and frequency, PSA, PSAdt and PSAvel.
| n = 660 | GS < 7 (45) | GS 7a (115) | GS 7b (222) | GS 8 (118) | GS > 8 (160) | Chi2 r, p value |
|---|---|---|---|---|---|---|
| PET/CT positive | 20 | 61 | 178 | 107 | 134 | 0.284; p < 0.001 |
| AT | 9 | 25 | 75 | 52 | 82 | 0.226; p < 0.001 |
| Local recurrence | 12 | 30 | 61 | 37 | 48 | 0.035; n. s. |
| Metastases | 9 | 41 | 137 | 90 | 120 | 0.334; p < 0.001 |
| Site of M | 0.328; p < 0.001 | |||||
| Local M | 4 | 35 | 70 | 39 | 55 | |
| Distant M | 3 | 4 | 34 | 24 | 33 | |
| Local and | 2 | 2 | 33 | 27 | 32 | |
| Distant M | ||||||
| Number of M | 0.309; p < 0.001 | |||||
| Single M | 4 | 19 | 40 | 24 | 45 | |
| Multiple M | 5 | 22 | 97 | 66 | 75 | |
| Lymph node M | 7 | 33 | 106 | 72 | 81 | 0.204; p < 0.001 |
| Site of LN M | 0.200; p < 0.001 | |||||
| Local | 4 | 32 | 79 | 50 | 57 | |
| Distant | 1 | 1 | 5 | 10 | 6 | |
| Local and distant | 2 | 0 | 22 | 12 | 18 | |
| Bone M | 2 | 8 | 59 | 35 | 78 | 0.321; p < 0.001 |
| Other M (i. e. lung, soft tissue) | 1 | 2 | 5 | 14 | 7 | 0.084; p < 0.001 |
| PSA (ng/ml) | 0.125; p = 0.005 | |||||
| < 0.2 | 3 | 9 | 10 | 11 | 6 | |
| 0.2 to <0.5 | 8 | 19 | 21 | 9 | 19 | |
| 0.5 to <1 | 8 | 11 | 31 | 15 | 16 | |
| 1 to < 2 | 8 | 17 | 43 | 10 | 23 | |
| 2 to <5 | 10 | 36 | 57 | 23 | 36 | |
| ≥ 5 | 8 | 23 | 60 | 50 | 60 | |
| PSAdt (month) | p = −0.096; n. s. | |||||
| < 6 | 8 | 35 | 67 | 34 | 60 | |
| 6 to <12 | 7 | 22 | 46 | 21 | 33 | |
| ≥ 12 | 30 | 58 | 109 | 63 | 67 |
| n = 225 | GS < 7(16) | GS 7a(40) | GS 7b(61) | GS 8(30) | GS > 8(78) | Chi2 r, p value |
|---|---|---|---|---|---|---|
| PSAvel (ng/ml/y) | 0.207; n. s. | |||||
| < 1 | 13 | 24 | 29 | 12 | 34 | |
| 1 to <2 | 0 | 8 | 11 | 3 | 11 | |
| 2 to 5 | 2 | 5 | 7 | 7 | 12 | |
| >5 | 1 | 3 | 14 | 8 | 2 |
LN, lymph node; M, metastases; (n), number of patients; data are percentage of patients; p < 0.05 is considered significant; r, Pearson correlation coefficient, PSA, prostate-specific antigen; PSAdt/vel, PSA doubling time/velocity; AT, anti-androgen therapy.